• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    10/27/23 5:31:13 PM ET
    $ALGS
    $ALLR
    $CFRX
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALGS alert in real time by email

    Gainers

    • Coherus BioSciences (NASDAQ:CHRS) shares moved upwards by 11.7% to $2.95 during Friday's after-market session. Today's trading volume for this security ended up closing at 1.4 million shares, which is 55.1 percent of its average volume over the last 100 days. The company's market cap stands at $313.8 million.
    • Aligos Therapeutics (NASDAQ:ALGS) stock increased by 11.56% to $0.69. The market value of their outstanding shares is at $30.0 million.
    • ContraFect (NASDAQ:CFRX) shares moved upwards by 11.36% to $0.3. The market value of their outstanding shares is at $1.6 million.
    • ProKidney (NASDAQ:PROK) shares rose 9.61% to $1.65. The market value of their outstanding shares is at $101.6 million.
    • Virpax Pharmaceuticals (NASDAQ:VRPX) stock moved upwards by 8.1% to $0.8. The company's market cap stands at $9.3 million.
    • Reviva Pharmaceuticals (NASDAQ:RVPH) shares increased by 7.99% to $4.05. The company's market cap stands at $91.7 million.

    Losers

    • Connect Biopharma Hldgs (NASDAQ:CNTB) stock declined by 10.0% to $1.24 during Friday's after-market session. The market value of their outstanding shares is at $68.3 million.
    • SeaStar Medical Holding (NASDAQ:ICU) stock decreased by 8.0% to $0.94. At the close, SeaStar Medical Holding's trading volume reached 8.5 million shares. This is 64.8% of its average volume over the last 100 days. The company's market cap stands at $18.2 million.
    • Allarity Therapeutics (NASDAQ:ALLR) shares fell 6.93% to $0.56. The company's market cap stands at $2.3 million.
    • Lipella Pharmaceuticals (NASDAQ:LIPO) stock decreased by 6.41% to $1.17. The company's market cap stands at $6.7 million.
    • Sight Sciences (NASDAQ:SGHT) stock fell 5.34% to $1.42. This security traded at a volume of 152.4K shares come close, making up 49.1% of its average volume over the last 100 days. The company's market cap stands at $69.0 million.
    • MSP Recovery (NASDAQ:LIFW) stock fell 5.33% to $1.6. This security traded at a volume of 210.3K shares come close, making up 12.1% of its average volume over the last 100 days. The company's market cap stands at $21.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALGS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALGS
    $ALLR
    $CFRX
    $CHRS

    CompanyDatePrice TargetRatingAnalyst
    Aligos Therapeutics Inc.
    $ALGS
    3/19/2026$48.00Buy
    Jefferies
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    3/5/2026Buy → Hold
    D. Boral Capital
    Coherus Oncology Inc.
    $CHRS
    1/23/2026$10.00Outperform
    Oppenheimer
    Sight Sciences Inc.
    $SGHT
    1/5/2026$9.00Neutral → Overweight
    Piper Sandler
    ProKidney Corp.
    $PROK
    12/16/2025$12.00Buy
    H.C. Wainwright
    Connect Biopharma Holdings Limited
    $CNTB
    12/1/2025$9.00Buy
    Lake Street
    Connect Biopharma Holdings Limited
    $CNTB
    10/31/2025$10.00Buy
    BTIG Research
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    9/29/2025$2.00Buy
    Chardan Capital Markets
    More analyst ratings

    $ALGS
    $ALLR
    $CFRX
    $CHRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baird Jennifer A bought $987 worth of shares (4,200 units at $0.24), increasing direct ownership by 13% to 36,200 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    12/22/25 6:55:38 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Director Encrantz Staffan bought $115,963 worth of shares (13,958 units at $8.31), increasing direct ownership by 1% to 1,391,922 units (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    12/18/25 6:10:08 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Messinger Michael bought $5,098 worth of shares (14,500 units at $0.35), increasing direct ownership by 483% to 17,500 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    12/11/25 6:49:59 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ALGS
    $ALLR
    $CFRX
    $CHRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Aligos Therapeutics with a new price target

    Jefferies resumed coverage of Aligos Therapeutics with a rating of Buy and set a new price target of $48.00

    3/19/26 8:25:43 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Reviva Pharmaceuticals downgraded by D. Boral Capital

    D. Boral Capital downgraded Reviva Pharmaceuticals from Buy to Hold

    3/5/26 8:53:11 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Coherus BioSciences with a new price target

    Oppenheimer initiated coverage of Coherus BioSciences with a rating of Outperform and set a new price target of $10.00

    1/23/26 8:18:28 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    $ALLR
    $CFRX
    $CHRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Prabhu Narayan

    4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)

    3/20/26 5:00:47 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Bhat Laxminarayan

    4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)

    3/20/26 5:00:20 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Huang James

    3 - Connect Biopharma Holdings Ltd (0001835268) (Issuer)

    3/18/26 4:30:39 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALGS
    $ALLR
    $CFRX
    $CHRS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

    Added top-rated children's hospitals to QUELIMMUNE™ pediatric Acute Kidney Injury (AKI) customer base Completed enrollment in FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry Exceeded 50% enrollment milestone in pivotal trial of SCD therapy in adult patients with AKI Advanced pipeline indications with initiation of cardio-renal clinical trial Webcast today at 4:30 pm Eastern Time DENVER, March 25, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months and yea

    3/25/26 4:05:00 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

    WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Greg Madison as Chief Commercial Officer. In this role, Mr. Madison will drive ProKidney's commercial strategy as the Company advances towards the potential commercialization of rilparencel. "Greg is a seasoned commercial biopharma executive with a proven track record of building high-performing organizations, shaping strategy, and preparing innovative therapies for market," said Bruce Culleton, M.D., CEO of ProKidney. "He brings valuable operation

    3/25/26 4:01:00 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering

    CUPERTINO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the closing on March 20, 2026 of its previously announced public offering with healthcare focused institutional investors for the purchase and sale of 6,666,667 shares of its common stock (or common stock equivalents in lieu thereof) together with Series G warrants to purchase up to 6,666,667 shares of common stock (the "Series G Warrants") and Series H warr

    3/23/26 8:00:00 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALGS
    $ALLR
    $CFRX
    $CHRS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Coherus Oncology Inc.

    SCHEDULE 13G/A - Coherus Oncology, Inc. (0001512762) (Subject)

    3/26/26 5:12:27 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by SeaStar Medical Holding Corporation

    10-K - SeaStar Medical Holding Corp (0001831868) (Filer)

    3/25/26 4:45:31 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    SeaStar Medical Holding Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - SeaStar Medical Holding Corp (0001831868) (Filer)

    3/25/26 4:10:15 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ALGS
    $ALLR
    $CFRX
    $CHRS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for CIMERLI issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug CIMERLI (SUPPL-5) with active ingredient RANIBIZUMAB-EQRN has changed to 'Approval' on 05/21/2024. Application Category: BLA, Application Number: 761165, Application Classification:

    5/22/24 9:41:01 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for LOQTORZI issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug LOQTORZI (SUPPL-1) with active ingredient TORIPALIMAB-TPZI has changed to 'Approval' on 04/22/2024. Application Category: BLA, Application Number: 761240, Application Classification:

    4/23/24 4:41:07 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for UDENYCA issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug UDENYCA (SUPPL-15) with active ingredient PEGFILGRASTIM-CBQV has changed to 'Approval' on 12/22/2023. Application Category: BLA, Application Number: 761039, Application Classification:

    12/27/23 4:38:39 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    $ALLR
    $CFRX
    $CHRS
    Leadership Updates

    Live Leadership Updates

    View All

    ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

    WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Greg Madison as Chief Commercial Officer. In this role, Mr. Madison will drive ProKidney's commercial strategy as the Company advances towards the potential commercialization of rilparencel. "Greg is a seasoned commercial biopharma executive with a proven track record of building high-performing organizations, shaping strategy, and preparing innovative therapies for market," said Bruce Culleton, M.D., CEO of ProKidney. "He brings valuable operation

    3/25/26 4:01:00 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer

    SOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (("Aligos", NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of James Hassard, MBA as Executive Vice President, Chief Commercial Officer, effective immediately. Mr. Hassard will lead and build the Company's global commercial capabilities and serve as a member of Aligos' Senior Leadership Team. Mr. Hassard is a seasoned executive with extensive experience building commercial organizations across multiple therapeutic areas. "As we continue to progress the Phase 2 B-

    1/13/26 8:00:00 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer

    ALISO VIEJO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a late-stage biopharmaceutical company, today announced the appointment of Jean-Frédéric Viret, Ph.D., as the company's Chief Financial Officer (CFO). Dr. Viret brings over two decades of corporate finance experience in the life sciences industry, leading companies from early-stage clinical development through post-commercialization. At SpyGlass, he will lead the finance and accounting functions as the company advances the Bimatoprost Drug Pad-IOL System (BIM-IOL System) toward late-stage development and potential commercialization. "We are excited to welcome Jean to SpyGlass Pharma as we continue to advance our clin

    1/6/26 8:00:00 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    $ALLR
    $CFRX
    $CHRS
    Financials

    Live finance-specific insights

    View All

    SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

    Added top-rated children's hospitals to QUELIMMUNE™ pediatric Acute Kidney Injury (AKI) customer base Completed enrollment in FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry Exceeded 50% enrollment milestone in pivotal trial of SCD therapy in adult patients with AKI Advanced pipeline indications with initiation of cardio-renal clinical trial Webcast today at 4:30 pm Eastern Time DENVER, March 25, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months and yea

    3/25/26 4:05:00 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    SeaStar Medical to Report Fourth Quarter and Year-End 2025 Financial Results on March 25, 2026

    DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its fourth quarter and year-end 2025 financial results after market close on Wednesday, March 25, 2026, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, March 25, 2026, at 4:30 p.m. ET / 2:30 p.m. MT  Webcast:The live webcast and replay can be found here.  Register for the call:Preregistration is required to attend the live call and can be accessed h

    3/18/26 4:05:00 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance

    MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the fourth quarter and full year ended December 31, 2025 and initiated financial guidance for full year 2026.   Recent Financial Highlights Generated fourth quarter 2025 total revenue of $20.4 million, an increase of 7% compared to the same period in the prior year, and full year 2025 total revenue of $77.4 million, a decrease of 3% compared to full year 2

    3/4/26 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $ALGS
    $ALLR
    $CFRX
    $CHRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

    SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

    11/14/24 6:57:50 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

    SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

    11/14/24 6:19:11 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care